Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care-Reference-Cited by-同舟云学术

Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care

Published:2011-02 Issue:3 Volume:128 Page:277-286
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Ruiz Miguel A.,Zamorano Enric,García-Campayo Javier,Pardo Antonio,Freire Olga,Rejas Javier

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference45 articles.

1. Disability and quality of life impact of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project;Alonso;Acta Psychiatr. Scand.,2004

2. Cost of affective disorders in Europe;Andlin-Sobocki;Eur. J. Neurol.,2005

3. Generalized worry disorder: a review of DSM-IV generalized anxiety disorder and options for DSM-V;Andrews;Depress. Anxiety,2010

4. High prevalence of mental disorders in primary care;Ansseau;J. Affect. Disord.,2004

5. Ayuso-Mateos, J.L., Nuevo, R., Verdes, E., Naidoo, N., Chatterji, S., 2010. From depressive symptoms to depressive disorders: the relevance of thresholds. Br. J. Psychiatr. 196 (5), 365–371.

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generalized anxiety disorder screening scores are associated with greater treatment need among Veterans with depression;Journal of Psychiatric Research;2024-09

2. Optimizing generalized anxiety disorder screening in young adults perinatally affected by HIV: A psychometric analysis;Journal of Mood & Anxiety Disorders;2024-09

3. Stress Among the Undergraduate Students in Public Universities in Kenya;Advances in Higher Education and Professional Development;2024-08-30

4. Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial;The Lancet Respiratory Medicine;2024-08

5. Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial;Asian Journal of Psychiatry;2024-07